Association Between Topical Calcineurin Inhibitor Use and Keratinocyte Carcinoma Risk Among Adults With Atopic Dermatitis

IMPORTANCE: Topical calcineurin inhibitors (TCIs), primarily used to treat atopic dermatitis (AD), carry a black box label warning users about the potential for increased skin cancer risk. The risk associated with keratinocyte carcinoma (KC), the most common cancer, defined as basal cell carcinoma (...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:JAMA Dermatol
Egile Nagusiak: Asgari, Maryam M., Tsai, Ai-Lin, Avalos, Lyndsay, Sokil, Monica, Quesenberry, Charles P.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: American Medical Association 2020
Gaiak:
Original Investigation
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7557510/
https://ncbi.nlm.nih.gov/pubmed/32785626
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamadermatol.2020.2240
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak